GlassScriptPhysician profile
Kateryna Kurako
NPI 1962835538
$2,775.26
in general payments reported to CMS, 2019-2025
30 companies · $664 in 2025
The $664 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $336 · 2021: $327 · 2022: $383 · 2023: $153 · 2024: $518 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,334.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $813.68 | 2021-2025 | |
| Allergan, INC. | $431.34 | 2019-2021 | |
| Lundbeck LLC | $231.51 | 2020-2025 | Vyepti |
| Livanova USA, INC. | $177.86 | 2019-2020 | |
| Ucb, INC. | $149.61 | 2025 | Fintepla |
| Horizon Therapeutics Plc | $113.07 | 2022-2023 | Uplizna |
| Acadia Pharmaceuticals INC | $86.75 | 2024-2025 | Nuplazid, Daybue |
| Amgen INC. | $81.57 | 2020-2024 | Uplizna |
| Biogen, INC. | $63.27 | 2024-2025 | Leqembi, Skyclarys |
| Otsuka America Pharmaceutical, INC. | $55.13 | 2024-2025 | Rexulti |
| Globus Medical, INC. | $52.94 | 2025 | Senza |
| Novartis Pharmaceuticals Corporation | $50.24 | 2024-2025 | |
| Grifols USA, LLC | $50.04 | 2022 | |
| Pfizer INC. | $49.46 | 2024 | |
| Medtronic, INC. | $42.99 | 2023 | Intellis Adaptivestim |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $35.23 | 2022-2025 | Hizentra |
| Tanabe Pharma America, INC. | $27.45 | 2025 | Radicava |
| Alnylam Pharmaceuticals INC. | $26.75 | 2025 | Givlaari |
| Argenx US, INC. | $25.60 | 2024 | Vyvgart Hytrulo |
| Xeris Pharmaceuticals, INC. | $23.59 | 2025 | Keveyis |
| Revance Therapeutics, INC. | $20.17 | 2024 | Daxxify |
| Nevro Corp. | $19.77 | 2024 | Senza |
| Neurelis, INC. | $19.77 | 2024 | Valtoco |
| Kyowa Kirin, INC. | $19.61 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.25 | 2020 | |
| Impel Pharmaceuticals INC. | $19.05 | 2023 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $18.55 | 2022 | |
| Vanda Pharmaceuticals INC. | $18.05 | 2025 | Ponvory |
| Lilly USA, LLC | $16.86 | 2020 | |
| Emd Serono, INC. | $16.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kateryna Kurako listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.